Overview

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Status:
Not yet recruiting

Trial end date:
2037-02-01

Target enrollment:

Participant gender:

Summary

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.

Phase:

Phase 3

Details

Lead Sponsor:

NRG Oncology

Collaborators:

Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Southwest Oncology Group